BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 2578050)

  • 1. Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria.
    Roberts WN; Wilson JG; Wong W; Jenkins DE; Fearon DT; Austen KF; Nicholson-Weller A
    J Immunol; 1985 Jan; 134(1):512-7. PubMed ID: 2578050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5430-4. PubMed ID: 6225118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
    Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
    J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor.
    Fischer E; Appay MD; Cook J; Kazatchkine MD
    J Immunol; 1986 Feb; 136(4):1373-7. PubMed ID: 2418113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
    Nicholson-Weller A; March JP; Rosenfeld SI; Austen KF
    Proc Natl Acad Sci U S A; 1983 Aug; 80(16):5066-70. PubMed ID: 6576376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
    Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
    J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.
    Hänsch GM; Schönermark S; Roelcke D
    J Clin Invest; 1987 Jul; 80(1):7-12. PubMed ID: 3597779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the alternative pathway of complement by pH.
    Fishelson Z; Horstmann RD; Müller-Eberhard HJ
    J Immunol; 1987 May; 138(10):3392-5. PubMed ID: 2952717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythrocyte membrane protein deficiencies in paroxysmal nocturnal hemoglobinuria.
    Schultz DR
    Am J Med; 1989 Sep; 87(3N):22N-29N. PubMed ID: 2484793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies.
    Daha MR; Bloem AC; Ballieux RE
    J Immunol; 1984 Mar; 132(3):1197-1201. PubMed ID: 6229578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of CR1- and membrane cofactor protein-like proteins of two primates.
    Nickells MW; Atkinson JP
    J Immunol; 1990 Jun; 144(11):4262-8. PubMed ID: 2140391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding and catabolism of aggregated immunoglobulins containing C3b by U937 cells.
    Mehta RL; Takahashi H; Rudick RA; Knutson DW
    J Immunol; 1986 Mar; 136(5):1765-71. PubMed ID: 2936811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
    Parker CJ; Wiedmer T; Sims PJ; Rosse WF
    J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered expression of gangliosides in erythrocytes of paroxysmal nocturnal hemoglobinuria.
    Nakakuma H; Kawaguchi T; Horikawa K; Hidaka M; Yonemura Y; Kawakita M; Kagimoto T; Iwamori M; Nagai Y; Takatsuki K
    J Clin Invest; 1990 May; 85(5):1456-61. PubMed ID: 2185273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high m.w. form of decay-accelerating factor (DAF-2) exhibits size abnormalities in paroxysmal nocturnal hemoglobinuria erythrocytes.
    Kinoshita T; Rosenfeld SI; Nussenzweig V
    J Immunol; 1987 May; 138(9):2994-8. PubMed ID: 2437202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
    Medof ME; Kinoshita T; Silber R; Nussenzweig V
    Proc Natl Acad Sci U S A; 1985 May; 82(9):2980-4. PubMed ID: 2581259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.